Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis

Abstract

Core evidence clinical impact summary for lumiracoxib in osteoarthritisLumiracoxib has a similar CV risk profile as ibuprofen, and a similar CV profile as naproxen in patients taking aspirin. Lumiracoxib has an increased risk of CV events compared with naproxen in patients not taking aspirin continued overleaf... AbstractIntroduction: The symptoms of osteoarthritis (OA) include joint pain, stiffness, and a reduced ability to perform normal daily activities, which result in decreased quality of life. There is currently no known cure or means of preventing the progression of joint damage due to OA. Therefore, treatment focuses on the control of symptoms, including the use of various agents [including nonselective and selective nonsteroidal antiinflammatory drugs (NSAIDs)] to provide pain relief and reduce inflammation. Lumiracoxib is a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of OA.

Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD

“…As shown in Figure 1 , the synthesis of PGs and TX involves the hydrolysis of cellular phospholipids via the action of phospholipase A 2 (PLA 2 ) enzyme to produce free AA. AA is converted to unstable prostaglandin H 2 (PGH 2 ) by COX activity, and then to main prostanoids PGI 2 , TXA 2 , PGD 2 , PGE 2 and PGF 2 via their respective synthases PGIS, thromboxane A synthase (TXAS), prostaglandin D synthase (PGDS), prostaglandin E 2 synthases (PGESs) and prostaglandin F synthase (PGFS) ( 92 , 93 ). Currently, there are nine known prostanoid receptors expressed in different cell types, namely IP for PGI 2 , TP for TXA 2 , DP 1-2 for PGD 2 , EP 1-4 for PGE 2 , and FP for PGF 2 .…”